Dr. Rosenblum has been at ActivX since January 2001. He is responsible for overseeing biological aspects of the company’s drug discovery programs, spanning target selection to submitting reports to FDA. He was one of the original scientists at the company, and has been involved in many facets of the company’s evolution. He was ActivX's project leader for a collaboration with Kyorin that resulted in the discovery and development of the DPP-4 inhibitor bisegliptin (KRP-104), which has completed worldwide Phase 2 clinical study. Jonathan also served as the Principal Investigator for an SBIR grant (Phase 1 and Phase 2) from the National Institutes of Health, and has served as a study section member at the NIH. Prior to ActivX, Jonathan trained as an NIH postdoctoral fellow in the laboratory of Nobel Laureate Günter Blobel at the Rockefeller University. While at Rockefeller, Jonathan used proteomics and molecular cell biology to characterize mechanisms of nuclear protein transport. Prior to Rockefeller, Jonathan received his Ph.D. in Macromolecular and Cellular Structure and Chemistry as a National Science Foundation fellow at The Scripps Research Institute. Jonathan received a Bachelor of Arts degree in chemistry, magna cum laude, from the University of Pennsylvania, where he was also elected to Phi Beta Kappa, having been a Benjamin Franklin Scholar. Specialties: Drug discovery, biochemistry, enzymology, high throughput screening, proteomics, proteases, kinases